Although anti-EGFR antibodies are likely to be used in the first-line treatment of RAS wild-type, left-sided colorectal cancer, there is no clear evidence for the efficacy of angiogenesis inhibitors in subsequent second-line treatment. Here, EGFR is linked to colorectal cancer.